14.02
-0.34 (-2.37%)
| Previous Close | 14.36 |
| Open | 14.80 |
| Volume | 1,227,836 |
| Avg. Volume (3M) | 233,411 |
| Market Cap | 1,860,269,696 |
| Price / Sales | 28.50 |
| Price / Book | 3.26 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2026 |
| Operating Margin (TTM) | -633.21% |
| Diluted EPS (TTM) | -1.24 |
| Quarterly Revenue Growth (YOY) | -6.80% |
| Total Debt/Equity (MRQ) | 27.34% |
| Current Ratio (MRQ) | 0.960 |
| Operating Cash Flow (TTM) | -42.54 M |
| Levered Free Cash Flow (TTM) | -13.46 M |
| Return on Assets (TTM) | -4.85% |
| Return on Equity (TTM) | -21.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Mesoblast Limited | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Average | 1.00 |
|
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.06% |
| % Held by Institutions | 3.10% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Summit X, Llc | 30 Jun 2025 | 199,295 |
| Arax Advisory Partners | 31 Dec 2025 | 166,482 |
| Penbrook Management Llc | 31 Dec 2025 | 87,575 |
| Prosperity Wealth Management, Inc. | 30 Sep 2025 | 49,950 |
| Rialto Wealth Management, Llc | 31 Dec 2025 | 46,500 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 Jan 2026 | Announcement | Ryoncil® Net Revenues Increase for the Quarter to US$30M |
| 26 Jan 2026 | Announcement | Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment |
| 18 Jan 2026 | Announcement | FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy |
| 08 Jan 2026 | Announcement | Ryoncil® Sales Increase 60% in December Quarter to US$35.1M |
| 01 Jan 2026 | Announcement | Mesoblast Announces Changes to Board of Directors' Leadership Roles |
| 29 Dec 2025 | Announcement | Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |